A detailed history of Hancock Whitney Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hancock Whitney Corp holds 2,708 shares of VRTX stock, worth $1.26 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,708
Previous 2,787 2.83%
Holding current value
$1.26 Million
Previous $1.31 Million 3.6%
% of portfolio
0.04%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $36,340 - $39,956
-79 Reduced 2.83%
2,708 $1.26 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $1,964 - $2,427
-5 Reduced 0.18%
2,787 $1.31 Million
Q1 2024

May 16, 2024

BUY
$407.69 - $446.08 $41,176 - $45,054
101 Added 3.75%
2,792 $1.17 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $31,899 - $38,193
-93 Reduced 3.34%
2,691 $1.09 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $11,159 - $11,961
33 Added 1.2%
2,784 $968,000
Q2 2023

Nov 13, 2023

BUY
$314.42 - $351.91 $65,399 - $73,197
208 Added 8.18%
2,751 $968,000
Q2 2023

Aug 10, 2023

BUY
$314.42 - $351.91 $65,399 - $73,197
208 Added 8.18%
2,751 $968,000
Q1 2023

Nov 13, 2023

BUY
$283.23 - $323.1 $205,341 - $234,247
725 Added 39.88%
2,543 $801,000
Q1 2023

May 16, 2023

BUY
$283.23 - $323.1 $205,341 - $234,247
725 Added 39.88%
2,543 $801,000
Q4 2022

Nov 13, 2023

SELL
$285.76 - $321.48 $266,614 - $299,940
-933 Reduced 33.91%
1,818 $525,000
Q4 2022

Feb 03, 2023

BUY
$285.76 - $321.48 $571 - $642
2 Added 0.11%
1,818 $525,000
Q3 2022

Oct 26, 2022

BUY
$273.83 - $305.53 $4,928 - $5,499
18 Added 1.0%
1,816 $526,000
Q2 2022

Aug 08, 2022

SELL
$234.96 - $292.55 $68,138 - $84,839
-290 Reduced 13.89%
1,798 $507,000
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $22,363 - $26,357
101 Added 5.08%
2,088 $545,000
Q4 2021

Jan 25, 2022

BUY
$177.01 - $223.45 $4,248 - $5,362
24 Added 1.22%
1,987 $436,000
Q3 2021

Nov 04, 2021

BUY
$181.39 - $202.99 $4,353 - $4,871
24 Added 1.24%
1,963 $356,000
Q2 2021

Aug 09, 2021

SELL
$187.49 - $221.1 $21,186 - $24,984
-113 Reduced 5.51%
1,939 $391,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $362,906 - $423,016
-1,753 Reduced 46.07%
2,052 $441,000
Q4 2020

Feb 09, 2021

SELL
$207.01 - $276.09 $7,245 - $9,663
-35 Reduced 0.91%
3,805 $899,000
Q3 2020

Nov 05, 2020

SELL
$255.65 - $303.1 $112,486 - $133,364
-440 Reduced 10.28%
3,840 $1.05 Million
Q2 2020

Jul 30, 2020

SELL
$225.48 - $295.8 $12,401 - $16,269
-55 Reduced 1.27%
4,280 $1.24 Million
Q1 2020

May 08, 2020

BUY
$199.77 - $247.81 $26,968 - $33,454
135 Added 3.21%
4,335 $1.03 Million
Q4 2019

Feb 06, 2020

SELL
$166.71 - $223.91 $33,508 - $45,005
-201 Reduced 4.57%
4,200 $920,000
Q3 2019

Oct 29, 2019

SELL
$166.23 - $187.09 $22,274 - $25,070
-134 Reduced 2.95%
4,401 $746,000
Q2 2019

Aug 29, 2019

SELL
$164.61 - $190.37 $8,395 - $9,708
-51 Reduced 1.11%
4,535 $832,000
Q1 2019

May 13, 2019

BUY
$163.73 - $194.7 $5,730 - $6,814
35 Added 0.77%
4,586 $844,000
Q4 2018

Feb 15, 2019

BUY
$151.91 - $192.21 $293,945 - $371,926
1,935 Added 73.97%
4,551 $754,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $438,781 - $504,207
2,616 New
2,616 $504,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hancock Whitney Corp Portfolio

Follow Hancock Whitney Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.